EarningsQ4 2024 Earnings Report

Voyager Therapeutics (VYGR) Q4 2024 Earnings Report

0 Followers

Previous Report: Q3 2024

Next Report: Q1 2025

MX:VYGR Q4 2024 EPS Results

Actual EPS-$10.68

Consensus EPS-$6.64

Beat/MissMissed by -$4.04

One Year Ago EPS$22.62

MX:VYGR Q4 2024 Revenue Results

Actual Revenue$113.60M

Expected Revenue$300.04M

Beat/MissMissed by -$186.44M

YoY Revenue Growth-93.03%

Earnings Announcement Details

QuarterQ4 2024

Date03/11/2025

TimeAfter Close

Conference CallTuesday, March 11, 2025

MX:VYGR Upcoming Earnings

Voyager Therapeutics's next earnings date is estimated for November 10, 2026, based on past reporting schedules.

Q4 2024 Earnings Call Audio

MX:VYGR Q4 2024 Earnings Call

0:00 / 0:00

Q4 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2024 Earnings Call Summary

Q4 2024

Earnings Call Date:Mar 11, 2025|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.

Company Guidance

During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.

Strong Cash Position and Potential Milestone Payments

Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.

Advancements in Tau Silencing Program

The tau silencing gene therapy program, VY1706, moved forward into IND-enabling studies, showing 50% to 73% knockdown of tau messenger RNA in non-human primate studies.

Positive Results for Anti-Tau Antibody VY7523

VY7523 performed well in a single ascending dose study with no serious adverse events, showing dose-proportional pharmacokinetics and a CSF to serum ratio of 0.3%.

Promising External Data Supporting Anti-Tau Strategies

UCB's bepranemab demonstrated impact on tau accumulation, and further data from Merck and other companies are anticipated, which may support the potential of tau-targeted therapies.

Progress in Partnered Programs with Neurocrine

Two programs with Neurocrine are expected to enter the clinic or have an IND filed this year, indicating positive collaboration progress.

MX:VYGR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 10, 2026	2026 (Q3)	-7.58 / -	-8.505	―
Aug 06, 2026	2026 (Q2)	-8.76 / -7.24	-10.314	29.82% (+3.08)
May 07, 2026	2026 (Q1)	-9.97 / -8.50	-9.591	11.32% (+1.09)
Mar 09, 2026	2025 (Q4)	-9.25 / -8.32	-10.676	22.03% (+2.35)
Nov 10, 2025	2025 (Q3)	-9.43 / -8.50	-2.895	-193.75% (-5.61)
Aug 06, 2025	2025 (Q2)	-9.52 / -10.31	-3.257	-216.67% (-7.06)
May 06, 2025	2025 (Q1)	-8.12 / -9.59	-3.619	-165.00% (-5.97)
Mar 11, 2025	2024 (Q4)	-6.64 / -10.68	22.619	-147.20% (-33.30)
Nov 12, 2024	2024 (Q3)	-8.05 / -2.90	-10.676	72.88% (+7.78)
Aug 06, 2024	2024 (Q2)	-7.40 / -3.26	-9.229	64.71% (+5.97)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed